

**Interim report of
MEDICLIN Aktiengesellschaft**
for the period from 1 January 2021 to 31 March 2021

MEDICLIN: Key data on business development

| | Q1 2021 | Q1 2020 |
|--|---------|---------|
| Number of shares in millions | 47.5 | 47.5 |
| Number of cases (inpatient) | 22,067 | 28,727 |
| Number of beds as of 31.03. | 8,357 | 8,423 |
| Occupancy rate in % | 68.2 | 81.7 |
| Number of full-time employees (average number) | 7,155 | 7,558 |

| In thousands of € | Q1 2021 | Q1 2020 |
|---|---------|---------|
| Cash flow from operating activities | 14,012 | 12,471 |
| Cash flow from operating activities per share in € | 0.29 | 0.26 |
| Sales | 156,366 | 167,414 |
| EBITDA | 6,457 | 14,216 |
| EBITDA margin in % | 4.1 | 8.5 |
| EBIT (operating result) | -11,859 | -3,900 |
| EBIT margin in % | -7.6 | -2.3 |
| Financial result | -2,203 | -2,367 |
| Total consolidated result | -11,696 | -5,173 |
| Earnings per share in € | -0.24 | -0.11 |
| Gross capital expenditure (without right-of-use assets pursuant to IFRS 16) | 4,560 | 9,471 |
| Thereof subsidies | 505 | 756 |
| Interest coverage factor (EBITDA/interest result) | 2.9x | 6.0x |

| In thousands of € | 31.03.2021 | 31.12.2020 |
|--|------------|------------|
| Balance sheet total | 886,446 | 887,464 |
| Equity | 170,152 | 176,846 |
| Equity ratio in % | 19.2 | 19.9 |
| Return on equity ¹ in % | -9.1 | -5.1 |
| Financial liabilities (to banks) | 97,810 | 97,977 |
| Cash and cash equivalents | 100,126 | 100,437 |
| Adjusted net financial debt ² | 43,469 | 50,649 |
| Adjusted net financial debt ² /adjusted EBITDA ³ | 2.5x | 2.0x |

¹ Total consolidated result in the last 12 months/equity

² Adjusted average net financial debt in the last four quarters

³ Adjusted EBITDA in the last 12 months

Due to arithmetical reasons, calculation differences of +/- one unit (€, % etc.) may occur; percentage rates and changes in % were calculated on the basis of non-rounded € values.

Interim Group management report of MEDICLIN Aktiengesellschaft

for the period from 1 January 2021 to 31 March 2021

Report on the economic position for the first quarter of 2021

General statement on results of operations, financial position and net assets

Effects of pandemic continue to burden business performance

Other than in the first quarter of 2020, the economic and social effects of the coronavirus pandemic, i.e. the lockdown, rising capacity utilisation of intensive care units, keeping capacity available for COVID-19 patients and postponed treatment of acute conditions, weighed on the business performance of the entire three months of the first quarter of 2021. Therefore, a comparison of the two quarters has only limited significance.

Group EBIT below prior year despite cost cuts

A comparison of the two first quarters of the years in question shows that the Group's occupancy rate was 16.5 % below the previous year's value, while the number of treated inpatients declined by 23.2 %.

In the first quarter of 2021, Group sales of EUR 156.4 mill. were EUR 11.0 mill. or 6.6 % below the comparable prior-year quarter. Group sales include a total of EUR 7.6 mill. (previous year: EUR 3.7 mill.) of benefits for freeing capacity under the state protective shield to manage the effects of the pandemic and benefits from the coverage providers for additional expenses for hygiene measures and protective gear. Despite these benefits and a EUR 2.1 mill. decrease in expenses, the Group operating result was EUR –11.9 mill and thus EUR 8.0 mill. below the figure of EUR –3.9 mill. in the first quarter of 2020. This shows that the benefits under the state protective shield that have been reduced significantly and payments by the coverage providers compensate for only small part of the lower occupancy rates and higher costs.

Gross investments amounted to EUR 4.6 mill. in the first three months of the 2021 financial year (Q1 2020: EUR 9.5 mill.), pertaining mainly to the reconstruction and expansion of clinics and the acquisition of medical equipment. Capital expenditure has been cut down in light of the current situation.

Cash and cash equivalents as of 31 March 2021 amounted to EUR 100.1 mill. (31.12.2020: EUR 100.4 mill.). Cash and cash equivalents contain a total of about EUR 56.0 mill. in expected repayments to be made in the course of 2021, in particular of benefits under the protective shield previously received. Furthermore, the cash and cash equivalents item includes about EUR 18.0 mill. in subsidies for the planned construction of a new clinic.

Outlook

The continuously rising number of Corona-infections since February 2021 and the foreseeable capacity bottlenecks in clinics with intensive care units mean that reliable estimates regarding the Group's business performance can still only be based on experience gained in the previous year. The sales and earnings performance in the full year will continue to be affected by the course of the pandemic and the benefits under the protective shield, which will be far lower in 2021. Currently, MEDICLIN assumes that occupancy rates at pre-Corona levels will not be achievable before the second half of the year 2021 as vaccinations are progressing only very slowly.

Results of operation, financial position and net assets

Results of operation

SALES AND EARNINGS PERFORMANCE OF THE GROUP

| | Q1 2021 | Q1 2020 |
|---|---------|---------|
| Group sales in millions of € | 156.4 | 167.4 |
| Raw materials and consumables used in millions of € | 28.5 | 29.1 |
| Cost of materials ratio in % | 18.2 | 17.4 |
| Staff costs in millions of € | 112.1 | 112.6 |
| Staff costs ratio in % | 71.7 | 67.3 |
| Depreciation and amortisation in millions of € | 18.3 | 18.1 |
| Other operating expenses in millions of € | 12.8 | 14.0 |
| Group operating result in millions of € | -11.9 | -3.9 |

Group sales in the first quarter of the 2021 financial year were EUR 11.0 mill. below the previous year's value. Despite higher expenses for hygiene measures and protective gear, the cost of raw materials and consumables used declined by EUR 0.6 mill., mainly due to a decline in catering services (EUR -0.9 mill.). Staff costs were EUR 0.5 mill. below the previous year due to a lower number of employees. Depreciation and amortisation developed as expected. The EUR 1.2 mill. decrease in other operating expenses was primarily due to lower maintenance and travel expenses. The Group operating result was EUR -11.9 mill.

The financial result amounted to EUR -2.2 mill. (Q1 2020: EUR -2.4 mill.). The total consolidated result attributable to shareholders of MEDICLIN Aktiengesellschaft therefore amounts to EUR -11.6 mill. (Q1 2020: EUR -5.1 mill.). Earnings per share came to EUR -0.24 (Q1 2020: EUR -0.11).

The sales and earnings performance at segment level is shown in the segment reporting section.

Financial position and net assets

Cash and cash equivalents as of 31 March 2021 amounted to EUR 100.1 mill. (31.12.2020: EUR 100.4 mill.). This item contains a total of about EUR 56.0 mill. in expected repayments to be made in the course of 2021, in particular of benefits under the protective shield previously received. Furthermore, the cash and cash equivalents item includes about EUR 18.0 mill. in subsidies for the planned construction of a new clinic.

LIQUIDITY

| In millions of € | Q1 2021 | Q1 2020 |
|---|--------------|-------------|
| Cash flow from operating activities | 14.0 | 12.5 |
| Thereof total consolidated result | -11.7 | -5.2 |
| Cash flow from investing activities | -0.8 | -7.6 |
| Cash flow from financing activities | -13.5 | -13.6 |
| Cash flow for the period | -0.3 | -8.7 |
| Cash and cash equivalents at the beginning of the period | 100.4 | 37.2 |
| Cash and cash equivalents at the end of the period | 100.1 | 28.5 |

There was no significant change in net assets as of the balance sheet date on 31 March 2021 compared to 31 December 2020. The changes in non-current liabilities were due, among other reasons, to a change in interest rate affecting pension provisions. The increase in current liabilities is attributable to benefits under the protective shield so far received and to higher vacation provisions as of the reporting date.

BALANCE SHEET STRUCTURE

| In millions of € | 31.03.2021 | In % of balance sheet total | 31.12.2020 | In % of balance sheet total |
|-------------------------------|--------------|-----------------------------|--------------|-----------------------------|
| Assets | | | | |
| Non-current assets | 668.5 | 75.4 | 683.6 | 77.0 |
| Current assets | 217.9 | 24.6 | 203.9 | 23.0 |
| | 886.4 | 100.0 | 887.5 | 100.0 |
| Equity and liabilities | | | | |
| Equity | 170.1 | 19.2 | 176.8 | 19.9 |
| Non-current liabilities | 520.8 | 58.7 | 539.3 | 60.8 |
| Current liabilities | 195.5 | 22.1 | 171.4 | 19.3 |
| | 886.4 | 100.0 | 887.5 | 100.0 |

Segment reporting

The business performance of the segments is subject to the same conditions as the Group performance. Benefits under the protective shield and payments by coverage providers included in the results of the post-acute segment amounted to EUR 4.9 mill. (Q1 2020: EUR 1.4 mill.), while the corresponding payments in the acute segment amounted to EUR 2.5 mill. (Q1 2020: EUR 2.3 mill.).

SALES

| In millions of € | Q1 2021 | Q1 2020 | Change in % |
|-------------------------------------|--------------|--------------|-------------|
| Post-acute | 93.2 | 99.8 | -6.6 |
| Acute | 58.9 | 62.8 | -6.3 |
| Other activities and reconciliation | 4.3 | 4.8 | -10.3 |
| Thereof nursing care business area | 3.9 | 3.8 | +2.3 |
| Group | 156.4 | 167.4 | -6.6 |

RAW MATERIALS AND CONSUMABLES USED

| | Q1 2021 | Q1 2020 | Change in % |
|---|---------|---------|-------------|
| Post-acute | | | |
| Raw materials and consumables used in millions of € | 18.0 | 18.7 | -4.0 |
| Cost of materials ratio in % | 19.3 | 18.8 | |
| Acute | | | |
| Raw materials and consumables used in millions of € | 15.8 | 15.4 | +2.2 |
| Cost of materials ratio in % | 26.8 | 24.6 | |

STAFF COSTS

| | Q1 2021 | Q1 2020 | Change in % |
|------------------------------|---------|---------|-------------|
| Post-acute | | | |
| Staff costs in millions of € | 59.2 | 60.0 | -1.4 |
| Staff costs ratio in % | 63.5 | 60.1 | |
| Acute | | | |
| Staff costs in millions of € | 38.2 | 38.4 | -0.6 |
| Staff costs ratio in % | 64.8 | 61.2 | |

SEGMENT RESULT

| In millions of € | Q1 2021 | Q1 2020 |
|-------------------------------------|--------------|-------------|
| Post-acute | -7.5 | -2.2 |
| Acute | -3.8 | -0.3 |
| Other activities and reconciliation | -0.6 | -1.4 |
| Group | -11.9 | -3.9 |

Employees

The average number of full-time employees went down quarter-by-quarter. The Group employed an average of 370 trainees in the first quarter of 2021 (Q1 2020: 350 trainees).

QUARTERLY AVERAGE OF NUMBER OF EMPLOYEES IN THE GROUP AND IN THE SEGMENTS

| Shown in full-time employees | Q1 2021 | Q1 2020 | Change |
|--|--------------|--------------|-------------|
| Post-acute | 3,874 | 4,095 | -221 |
| Acute | 2,063 | 2,192 | -129 |
| Other activities | 1,218 | 1,271 | -53 |
| Thereof nursing care business area | 209 | 193 | +16 |
| Thereof service business area (including administration) | 1,009 | 1,078 | -69 |
| Group | 7,155 | 7,558 | -403 |

Consolidated interim financial statements of MEDICLIN Aktiengesellschaft

for the period from 1 January 2021 to 31 March 2021

| | |
|----|--|
| 10 | Consolidated interim balance sheet as of 31 March 2021 |
| 12 | Consolidated interim profit and loss account |
| 13 | Consolidated interim statement of comprehensive income |
| 14 | Consolidated cash flow statement |
| 15 | Statement of changes in equity |
| 16 | Other information |

Consolidated interim balance sheet as of 31 March 2021

ASSETS

| In € | 31.03.2021 | 31.12.2020 |
|--|--------------------|--------------------|
| NON-CURRENT ASSETS | | |
| Goodwill and other intangible assets | | |
| Concessions, licences | 7,250,544 | 7,897,310 |
| Goodwill | 49,888,841 | 49,253,841 |
| Payments on account | 935,684 | 894,782 |
| | 58,075,069 | 58,045,933 |
| Property, plant and equipment | | |
| Land, land rights and buildings including buildings on third-party land | 130,379,380 | 123,468,597 |
| Right-of-use assets on land, land rights and buildings including buildings on third-party land | 358,568,095 | 371,099,404 |
| Technical equipment and machines | 12,996,141 | 13,274,913 |
| Operating and office equipment | 36,593,364 | 37,811,777 |
| Right-of-use assets on operating and office equipment | 2,572,395 | 2,643,079 |
| Payments on account and assets under construction | 15,850,676 | 23,740,512 |
| | 556,960,051 | 572,038,282 |
| Financial assets | | |
| Investment in stock of subsidiaries | 90,322 | 90,322 |
| Reinsurance cover | 764,510 | 764,510 |
| Other financial investments | 2,056 | 2,056 |
| | 856,888 | 856,888 |
| Other assets | | |
| Receivables pursuant to hospital financing law | 40,189,680 | 41,647,730 |
| | 40,189,680 | 41,647,730 |
| Deferred tax assets | 12,503,946 | 11,016,452 |
| | 668,585,634 | 683,605,285 |
| CURRENT ASSETS | | |
| Inventories | 9,378,240 | 9,341,672 |
| Trade receivables | 81,709,380 | 76,335,138 |
| Current income tax claims | 4,290,929 | 2,401,516 |
| Other financial assets | | |
| Other current financial assets | 4,901,805 | 5,178,148 |
| | 4,901,805 | 5,178,148 |
| Other assets | | |
| Prepaid expenses | 4,644,805 | 1,311,935 |
| Receivables pursuant to hospital financial law | 12,809,659 | 8,852,916 |
| | 17,454,464 | 10,164,851 |
| Cash and cash equivalents | 100,125,879 | 100,437,077 |
| | 217,860,697 | 203,858,402 |
| | 886,446,331 | 887,463,687 |

EQUITY AND LIABILITIES

| In € | 31.03.2021 | 31.12.2020 |
|--|--------------------|--------------------|
| EQUITY | | |
| Shares MEDICLIN Group | | |
| Subscribed capital | 47,500,000 | 47,500,000 |
| Capital reserve | 129,391,829 | 129,391,829 |
| Revenue reserve | 21,732,616 | 16,764,377 |
| Consolidated balance sheet result | -28,116,464 | -16,493,229 |
| | 170,507,981 | 177,162,977 |
| Non-controlling interests | -355,606 | -316,812 |
| | 170,152,375 | 176,846,165 |
| NON-CURRENT LIABILITIES | | |
| Financial liabilities | | |
| Liabilities to banks | 70,739,490 | 71,196,091 |
| | 70,739,490 | 71,196,091 |
| Lease liabilities | 322,840,207 | 334,874,917 |
| Pensions and similar commitments | 62,474,613 | 68,324,949 |
| Other provisions | 23,843,221 | 23,901,156 |
| Other financial liabilities | | |
| Miscellaneous financial liabilities | 0 | 0 |
| | 0 | 0 |
| Other payables | | |
| Liabilities pursuant to hospital financing law | 38,091,234 | 38,187,887 |
| Miscellaneous payables | 2,804,024 | 2,782,611 |
| | 40,895,258 | 40,970,498 |
| | 520,792,789 | 539,267,611 |
| CURRENT LIABILITIES | | |
| Trade payables | 10,399,415 | 11,307,664 |
| Financial liabilities | | |
| Liabilities to banks | 27,070,537 | 26,781,278 |
| | 27,070,537 | 26,781,278 |
| Lease liabilities | 54,070,197 | 54,009,475 |
| Other provisions | 14,817,309 | 15,530,311 |
| Other financial liabilities | | |
| Miscellaneous financial liabilities | 5,511,198 | 6,298,754 |
| | 5,511,198 | 6,298,754 |
| Other payables | | |
| Liabilities pursuant to hospital financing law | 13,163,006 | 11,388,381 |
| Miscellaneous payables | 70,469,505 | 46,034,048 |
| | 83,632,511 | 57,422,429 |
| | 195,501,167 | 171,349,911 |
| | 886,446,331 | 887,463,687 |

Consolidated interim profit and loss account

| In € | January – March 2021 | January – March 2020 |
|--|-------------------------|-------------------------|
| Sales | 156,365,750 | 167,413,685 |
| Other operating income | 3,542,240 | 2,566,025 |
| Total operating performance | 159,907,990 | 169,979,710 |
| Raw materials and consumables used | | |
| a) Cost of raw materials and supplies | – 17,795,201 | – 18,371,493 |
| b) Cost of purchased services | – 10,689,635 | – 10,747,960 |
| | – 28,484,836 | – 29,119,453 |
| Staff costs | | |
| a) Wages and salaries | – 95,493,673 | – 96,368,063 |
| b) Social security, pension and retirement | – 16,629,382 | – 16,277,771 |
| | – 112,123,055 | – 112,645,834 |
| Other operating expenses | – 12,843,146 | – 13,998,044 |
| Result before interest, taxes, depreciation and amortisation / EBITDA | 6,456,953 | 14,216,379 |
| Depreciation and amortisation | – 18,315,574 | – 18,116,540 |
| Operating result / EBIT | – 11,858,621 | – 3,900,161 |
| Financial result | | |
| a) Income from participations | 0 | 0 |
| b) Interest and similar income | 22,186 | 4,707 |
| c) Interest and similar expenses | – 2,225,129 | – 2,371,339 |
| | – 2,202,943 | – 2,366,632 |
| Result before tax | – 14,061,564 | – 6,266,793 |
| Taxes on income | 2,365,357 | 1,094,081 |
| Total consolidated result | – 11,696,207 | – 5,172,712 |
| Thereof attributable to shareholders of MEDICLIN AG | – 11,623,235 | – 5,116,245 |
| Thereof attributable to non-controlling interests | – 72,972 | – 56,467 |
| Total consolidated result attributable to shareholders of MEDICLIN AG per share | | |
| Undiluted in € | – 0.24 | – 0.11 |
| Diluted in € | – 0.24 | – 0.11 |

Consolidated interim statement of comprehensive income

| In € | January – March 2021 | January – March 2020 |
|--|-------------------------|-------------------------|
| Total consolidated result | -11,696,207 | -5,172,712 |
| Other comprehensive income | | |
| Revaluation from defined benefit plans and similar obligations | 5,942,878 | 2,190,904 |
| Taxes on income | -940,461 | -346,711 |
| Additions to value adjustments that are not reconciled to the total consolidated result | 5,002,417 | 1,844,193 |
| Thereof attributable to shareholders of MEDICLIN AG | 4,968,239 | 1,831,038 |
| Thereof attributable to non-controlling interests | 34,178 | 13,155 |
| Additions to value adjustments that are reconciled to the total consolidated result | 0 | 0 |
| Group comprehensive income | -6,693,790 | -3,328,519 |
| Thereof attributable to shareholders of MEDICLIN AG | -6,654,996 | -3,285,207 |
| Thereof attributable to non-controlling interests | -38,794 | -43,312 |

Consolidated cash flow statement

| In € | January – March 2021 | January – March 2020 |
|--|-------------------------|-------------------------|
| Total consolidated result | -11,696,207 | -5,172,712 |
| Result of finance activities | 2,202,943 | 2,366,632 |
| Result of income taxes | -2,365,357 | -1,094,081 |
| Operating result (EBIT) | -11,858,621 | -3,900,161 |
| Depreciation on fixed asset items | 18,315,574 | 18,116,540 |
| Result before interest, taxes, depreciation and amortisation (EBITDA) | 6,456,953 | 14,216,379 |
| Change in non-current provisions | -5,975,483 | -2,309,509 |
| Change in current provisions | -713,002 | -1,541,613 |
| Result from the disposal of fixed asset items | -4,942 | -16,645 |
| Result from other non-cash items | 1,075,370 | -271,182 |
| Change in other current assets | -12,185,298 | -3,469,916 |
| Change in other non-current liabilities | 20,657 | 17,155 |
| Change in other current liabilities | 27,269,266 | 6,623,078 |
| Payments received from interest | 22,186 | 8,673 |
| Income taxes paid | -1,953,411 | -785,726 |
| Cash flow from operating activities | 14,012,296 | 12,470,694 |
| Payments received from the disposal of fixed assets | 15,290 | 49,626 |
| From the disposal of property, plant and equipment | 15,290 | 49,626 |
| Payments received from investment subsidies | 3,346,711 | 488,636 |
| Cash used for investments | -4,204,708 | -8,089,294 |
| For intangible assets | -803,361 | -567,930 |
| For property, plant and equipment | -3,401,347 | -7,521,364 |
| Cash flow from investing activities | -842,707 | -7,551,032 |
| Repayment of lease liabilities | -11,190,896 | -11,016,917 |
| Repayment of financial liabilities | -541,471 | -437,681 |
| Interest payments for lease liabilities | -1,741,989 | -1,919,120 |
| Other interest payments | -6,431 | -258,441 |
| Cash flow from financing activities | -13,480,787 | -13,632,159 |
| Cash flow for the period | -311,198 | -8,712,497 |
| Cash and cash equivalents at the beginning of the period | 100,437,077 | 37,249,818 |
| Cash and cash equivalents at the end of the period | 100,125,879 | 28,537,321 |

The cash and cash equivalents at the end of the period correspond to the balance sheet item "cash and cash equivalents" and encompass only cash in hand and current bank credit balances.

Statement of changes in equity

| In € | Subscribed capital | Capital reserve | Revenue reserve | Consolidated balance sheet result | Shares MEDICLIN Group | Non-controlling interests | Total equity |
|-----------------------------------|--------------------|--------------------|--------------------|-----------------------------------|-----------------------|---------------------------|--------------------|
| As of 01.01.2020 | 47,500,000 | 129,391,829 | -29,568,498 | 43,669,121 | 190,992,452 | -245,990 | 190,746,462 |
| Total consolidated result | - | - | - | -5,116,245 | -5,116,245 | -56,467 | -5,172,712 |
| Other comprehensive income | - | - | 1,831,038 | - | 1,831,038 | 13,155 | 1,844,193 |
| Group comprehensive income | - | - | 1,831,038 | -5,116,245 | -3,285,207 | -43,312 | -3,328,519 |
| As of 31.03.2020 | 47,500,000 | 129,391,829 | -27,737,460 | 38,552,876 | 187,707,245 | -289,302 | 187,417,943 |

| In € | Subscribed capital | Capital reserve | Revenue reserve | Consolidated balance sheet result | Shares MEDICLIN Group | Non-controlling interests | Total equity |
|-----------------------------------|--------------------|--------------------|-------------------|-----------------------------------|-----------------------|---------------------------|--------------------|
| As of 01.01.2021 | 47,500,000 | 129,391,829 | 16,764,377 | -16,493,229 | 177,162,977 | -316,812 | 176,846,165 |
| Total consolidated result | - | - | - | -11,623,235 | -11,623,235 | -72,972 | -11,696,207 |
| Other comprehensive income | - | - | 4,968,239 | - | 4,968,239 | 34,178 | 5,002,417 |
| Group comprehensive income | - | - | 4,968,239 | -11,623,235 | -6,654,996 | -38,794 | -6,693,790 |
| As of 31.03.2021 | 47,500,000 | 129,391,829 | 21,732,616 | -28,116,464 | 170,507,981 | -355,606 | 170,152,375 |

Other information

General information

The unaudited consolidated interim financial statements of MEDICLIN for the first three months of the 2021 financial year were prepared in accordance with International Accounting Standard (IAS) 34. In the interim report, the Group principally applied the same accounting policies as in the consolidated financial statements for the 2020 financial year. The interim report should therefore be read in conjunction with the Company's 2020 Annual Report. The discount rate for pension provisions pursuant to IAS 19 is 0.9 % (31.12.2020: 0.4 %).

In its meeting on 11 January 2021 the Supervisory Board appointed Dr. York Dhein as a member of the Management Board of MEDICLIN AG as at 1 April 2021.

OIK-Immobilienfonds

In mid-2016 MEDICLIN filed a suit with the District Court of Offenburg claiming repayment of rental payments above the usual market rate. The Company assumes that the rents paid for the period 2005 to 2015 were higher than the usual market rents.

The suit was filed against current and former shareholders of the Company, who hold shares of the real estate fund into which the hospitals acquired and rented back between 1999 and 2001 were incorporated. The first oral hearing took place on 16 November 2018 at the District Court (Landgericht) of Offenburg.

MEDICLIN carefully weighed up the opportunities and risks of the suit in view of the fact that the subject matter of the legal dispute is highly complex, especially with regard to the evaluation whether rents conform to usual market rates, and that some of the very difficult questions of law involved have not yet been decided by the highest courts.

Therefore the Management Board is of the opinion that no changes to the balance sheet are required in this respect.

MEDICLIN Aktiengesellschaft

Offenburg, 3 May 2021

The Management Board

Key data on the MEDICLIN share

ISIN: DE 000659 5101; WKN: 659 510; TICKER: MED

| In € per share | Q1 2021 | Q1 2020 |
|---|---------|---------|
| Earnings, undiluted/diluted | -0.24 | -0.11 |
| Cash flow from operating activities | 0.29 | 0.26 |
| Book value ¹ as of 31.03. | 3.59 | 3.95 |
| Share price as of 31.03. | 4.32 | 4.26 |
| 52-weeks high | 4.78 | - |
| 52-weeks low | 3.60 | - |
| Market capitalisation as of 31.03. in millions of € | 205.2 | 202.4 |
| Number of shares in millions | 47.5 | 47.5 |

¹ Equity less non-controlling interests

Source: Deutsche Börse AG; Xetra/as of 13.04.2021

Forward-looking statements

This report contains forward-looking statements that are based on management's current expectations. Words such as "anticipate", "assume", "believe", "estimate", "expect", "intend", "can/could", "plan", "project", "should" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties that are based on the current assumptions and forecasts of MEDICLIN AG management. Should any of these risks and uncertainties materialise, or if the assumptions underlying any of the forward-looking statements prove incorrect, then the actual results may be materially different from those expressed or implied by such statements. MEDICLIN AG does not intend or assume any obligation to continuously update these forward-looking statements, so as to adapt them to events or developments that occur after the release of this interim report.

Financial calendar

26 February 2021

Disclosure of the preliminary figures for the 2020 financial year

26 March 2021

Annual press and analysts' conference for the 2020 financial year

3 May 2021

Publication of the interim report from 1 January 2021 to 31 March 2021

26 May 2021

Annual General Meeting

30 July 2021

Publication of the interim report from 1 January 2021 to 30 June 2021

2 November 2021

Publication of the interim report from 1 January 2021 to 30 September 2021

Adresses and imprint

MEDICLIN Aktiengesellschaft

Okenstraße 27

77652 Offenburg

Germany

Phone +49 (0) 7 81/4 88-0

Fax +49 (0) 7 81/4 88-133

E-mail info@mediclin.de

www.mediclin.de

Public Relations

Gabriele Eberle

Phone +49 (0) 7 81/4 88-180

Fax +49 (0) 7 81/4 88-184

E-mail gabriele.eberle@mediclin.de

Investor Relations

Alexandra Mühr

Phone +49 (0) 7 81/4 88-326

Fax +49 (0) 7 81/4 88-184

E-mail alexandra.muehr@mediclin.de

This Interim Report is also available in German.

Dieser Zwischenbericht liegt auch in deutscher Sprache vor.

This is a translation of the German Interim Report.

In case of divergence from the German version, the German version shall prevail.

www.mediclin.de